Rash associated with epidermal growth factor receptor inhibitors: a systematic review and meta-analysis of 194 randomized controlled trials
Abstract
Background: Rashes in patients treated with epidermal growth factor receptor inhibitors (EGFRIs) are closely related to better clinical outcomes. Multiple randomized controlled trials have evaluated rashes caused by EGFRIs. We conducted a meta-analysis of patients with tumors receiving EGFR-targeted therapy to determine the incidence and relative risk of rashes associated with these drugs.
Methods: Four databases (PubMed, Web of Science, Embase, and Cochrane) were systematically searched to find randomized controlled trials reporting the incidence of rash associated with EGFRIs from the time of database construction to May 15, 2025. Meta-analysis was used to calculate the total incidence and relative risk (RR) of all grades or each grade of rash.
Results: A total of 65,116 patients from 194 studies were included. The pooled incidences of all-grade rash and high-grade rash associated with EGFRIs were 52.30% (95% CI: 48.70%-55.80%) and 9.50% (95% CI: 8.70%-10.30%), respectively. The pooled RR suggested that EGFRIs were associated with a significantly increased risk of rash. Subgroup analysis and regression analysis showed that Asian populations, EGFR monoclonal antibodies (EGFR mAbs), phase III clinical trials, and EGFRI combination therapy may increase the occurrence of rash, whereas Aumolertinib had a significantly lower RR of rash. The type of tumor and the year of publication had no significant effect on the incidence of rash. The trim-and-fill method indicated that the…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 65,116 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.